Axsome Therapeutics, Inc. (AXSM)
148.75
-0.51
(-0.34%)
USD |
NASDAQ |
Dec 11, 16:00
147.00
-1.75
(-1.18%)
After-Hours: 06:23
Axsome Therapeutics Research and Development Expense (Quarterly): 40.04M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 87.83M |
| Fortress Biotech, Inc. | 0.208M |
| TG Therapeutics, Inc. | 40.88M |
| Karyopharm Therapeutics, Inc. | 30.42M |
| Viking Therapeutics, Inc. | 89.95M |